ERCP (endoscopic retrograde cholangiopancreatography) procedure registry at Methodist Dallas Medical Center
Endoscopic Retrograde Cholangiopancreatography Patient Registry
This registry collects information on ERCP procedures to see which patient and procedure factors affect post-ERCP pancreatitis for people over 15 who had ERCP at Methodist Dallas.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Methodist Health System Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT07490132 on ClinicalTrials.gov |
What this trial studies
This single-center registry will collect detailed clinical and procedural information for patients older than 15 who underwent ERCP at Methodist Dallas Medical Center between January 1, 2000 and December 31, 2025. Data elements will include patient risk factors, procedural techniques, and outcomes including occurrence of post-ERCP pancreatitis. Patients whose cannulation was via a surgical anastomosis or in whom cannulation was not attempted due to gastric outlet obstruction or an unidentifiable papilla are excluded. The registry is intended to support quality improvement efforts and future research on strategies to reduce post-ERCP pancreatitis.
Who should consider this trial
Good fit: People older than 15 who underwent ERCP at Methodist Dallas Medical Center between January 1, 2000 and December 31, 2025 and are included in the MDI registry are eligible.
Not a fit: Patients under 15, those with cannulation via a surgical anastomosis, or those in whom cannulation was not attempted due to gastric outlet obstruction or an unidentifiable papilla are not included and therefore will not benefit from this registry.
Why it matters
Potential benefit: If successful, the registry could identify modifiable risk factors and procedural practices that reduce the rate of post-ERCP pancreatitis and improve patient safety.
How similar studies have performed: Similar single-center and multicenter ERCP registries and targeted interventions (for example pancreatic stents and rectal NSAIDs) have identified risk factors and helped reduce post-ERCP pancreatitis in other settings, so the registry approach is established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients \>15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025 Exclusion Criteria: Patients \<15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.
Where this trial is running
Dallas, Texas
- Methodist Dallas Medical Center- Clinical Research Institute — Dallas, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Prashant Kedia, MD — Methodist Health System
- Study coordinator: Crystee Cooper, DHEd
- Email: ClinicalResearch@mhd.com
- Phone: 214-947-1280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.